FindTrial
Sign In

Adverse events of combined Dabrafenib Plus Trametinib in the treatment of tumors: a systematic review and meta-analysis.

Adverse events of combined Dabrafenib Plus Trametinib in the treatment of tumors: a systematic review and meta-analysis. - Adverse events of combined Dabrafenib Plus Trametinib in the treatment of tumors: a systematic review and meta-analysis.

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000041453
Enrollment
Unknown
Registered
2020-08-18
Start date
2020-08-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tumors

Interventions

None listed

Sponsors

3-9 Fukuura, Kanazawa, Yokohama 236-0004, Japan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: treated with dabrafenib and trametinib

Exclusion criteria

Exclusion criteria: Without frequency or category of adverse event

Design outcomes

Primary

MeasureTime frame
category fo adverse event—

Secondary

MeasureTime frame
frequency of adverse event—

Countries

Japan,Asia(except Japan),North America,South America,Australia,Europe,Africa

Contacts

Public ContactKou Chin

Yokohama city university Pulomonology

chinksmd@yahoo.co.jp045-352-7962

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026